4530.T Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 apr 2024 @ 08:15):

Stats
Dagens volum	111 900
Gjennomsnittsvolum	172 086
Markedsverdi	289.57B
EPS	¥0 ( 2024-04-10 )
Neste inntjeningsdato	( ¥0 ) 2024-07-11
Last Dividend	¥42.50 ( 2023-08-30 )
Next Dividend	¥0 ( N/A )
P/E	20.73
ATR14	¥1.279 (0.03%)

Volum Korrelasjon

Lang: 0.29 (neutral)

Kort: 0.29 (neutral)

Signal:(62.005) Neutral

Hisamitsu Pharmaceutical Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Hisamitsu Pharmaceutical Korrelasjon - Valuta/Råvare

-0.58
( weak negative )

-0.32
( neutral )

0.25
( neutral )

-0.24
( neutral )

-0.19
( neutral )

-0.61
( weak negative )

Hisamitsu Pharmaceutical Økonomi

Annual	2023
Omsetning:	¥141.71B
Bruttogevinst:	¥78.97B (55.73 %)
EPS:	¥181.62

FY	2023
Omsetning:	¥141.71B
Bruttogevinst:	¥78.97B (55.73 %)
EPS:	¥181.62

FY	2022
Omsetning:	¥128.33B
Bruttogevinst:	¥72.70B (56.65 %)
EPS:	¥148.00

FY	2022
Omsetning:	¥120.19B
Bruttogevinst:	¥70.07B (58.30 %)
EPS:	¥118.92

Financial Reports:

No articles found.

Hisamitsu Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0.250 (N/A)	¥0 (N/A)	¥0.250 (N/A)	¥0 (N/A)	¥42.50 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Hisamitsu Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.59 - Stable (8.11%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥7.00	2001-02-23
Last Dividend	¥42.50	2023-08-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	42	--
Total Paid Out	¥1 175.50	--
Avg. Dividend % Per Year	0.00%	--
Score	3.73	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.59
Div. Directional Score	7.68	--

Next Divdend (Est)
(2024-09-05)

¥0 Estimate 7.25 %

Dividend Stability

0.29 Very Poor

Dividend Score

3.73

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8058.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7315.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6564.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
5915.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4578.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
3834.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3085.T	Ex Dividend Knight	2023-06-29	Semi-Annually	0.00%
1951.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9507.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
8395.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0986	1.500	8.03	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0425	1.200	8.58	10.00	[0 - 0.3]
returnOnEquityTTM	0.0524	1.500	-0.529	-0.793	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.22	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.66	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.45	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00455	-1.500	9.92	-10.00	[0 - 0.6]
interestCoverageTTM	731.56	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	96.01	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	96.01	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00565	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.557	1.000	4.05	4.05	[0.2 - 0.8]
operatingProfitMarginTTM	0.0929	1.000	-0.142	-0.142	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.86	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.431	0.800	-0.460	-0.368	[0.5 - 2]
Total Score				10.77

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	20.68	1.000	8.01	0	[1 - 100]
returnOnEquityTTM	0.0524	2.50	-0.340	-0.793	[0.1 - 1.5]
freeCashFlowPerShareTTM	96.01	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.23	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	96.01	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.910	1.500	7.26	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0514	1.000	-1.216	0	[0.1 - 0.5]
Total Score				4.59

Hisamitsu Pharmaceutical

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.